EXECUTIVE ENGAGEMENTS
POOL
906
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
181
Interactions with Platform & by Email
PARTICIPANTS
36
Unique # Participated
VALIDATIONS
12
Responses Validated*
COMPANIES
32
Responses Validated*
* Login for a full stack data experience
DATE
JAN 2022
TABLES
22
PAGES
88
EDITION
6
PRICE
USD 5600
CODE
MCP22681
*Engagement stats are ongoing and dynamic
RESEARCH MODULES
EXECUTIVES
HIGHLIGHTS & REPORT INDEX
What's New for 2022?
» Global competitiveness and key competitor percentage market shares
» Market presence across multiple geographies - Strong/Active/Niche/Trivial
» Online interactive peer-to-peer collaborative bespoke updates
» Access to our digital archives and MarketGlass Research Platform
» Complimentary updates for one year
Amid the COVID-19 crisis, the global market for Rare Biomarkers Specimen Collection and Stabilization estimated at US$32 Billion in the year 2020, is projected to reach a revised size of US$59 Billion by 2027, growing at a CAGR of 9.2% over the analysis period 2020-2027. Circulating Cell Free DNA (ccfDNA), one of the segments analyzed in the report, is projected to record a 8.5% CAGR and reach US$23.6 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Circulating Tumor Cells (CTCs) segment is readjusted to a revised 9.6% CAGR for the next 7-year period.
The Rare Biomarkers Specimen Collection and Stabilization market in the U.S. is estimated at US$9.5 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$10.3 Billion by the year 2027 trailing a CAGR of 8.6% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.5% and 7.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 7.5% CAGR.
In the global Exosomes / Extracellular Vesicles segment, USA, Canada, Japan, China and Europe will drive the 10.4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$4.2 Billion in the year 2020 will reach a projected size of US$8.4 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$6.9 Billion by the year 2027.
SELECT PLAYERS
Advanced Cell Diagnostics, Inc.; Agena Bioscience; ANGLE plc; ApoCell, Inc.; AS One InternationalNTERNATIONAL; BioChain Institute, Inc.; Biolidics Limited; Biomatrica; Bio-Techne Corporation; BioVision, Inc.; Caltag Medsystems Limited; Cytomark Ltd.; DNA Genotek, Inc.; Epic Sciences; EpiGentek Group Inc.; F. Hoffmann-La Roche Ltd; Fluxion Biosciences, Inc.; Geno Technology Inc.; Genomax Technologies Pte Ltd.; GILUPI GmbH; LifeSpan BioSciences, Inc.; MagBio Genomics Inc.; Menarini Silicon Biosystems; MyBioSource.com; Norgen Biotek Corp.; Novus Biologicals, LLC; OraSure Technologies Inc.; Precision for Medicine, Inc.; Promega Corporation; QIAGEN; Rarecells Diagnostics SAS; RareCyte, Inc.; siemens Healthineers; SiO2 Materials Science; STEMCELL Technologies Inc.; Streck, Inc.; Thermo Fisher Scientific, Inc.; Vortex Biosciences; VyCAP B.V.
SEGMENTS
» Product Type (Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles, Circulating Cell Free RNA (ccfRNA) / miRNA) » End-Use (Research, Diagnostics)
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World
TABLE OF CONTENTS
| I. METHODOLOGY |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Influencer Market Insights |
| World Market Trajectories |
| Impact of Covid-19 and a Looming Global Recession |
| 2. FOCUS ON SELECT PLAYERS |
| 3. MARKET TRENDS & DRIVERS |
| 4. GLOBAL MARKET PERSPECTIVE |
| World Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020 & 2027 |
| World Current & Future Analysis for Circulating Cell Free DNA (ccfDNA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Circulating Cell Free DNA (ccfDNA) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| World Current & Future Analysis for Circulating Tumor Cells (CTCs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Circulating Tumor Cells (CTCs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| World Current & Future Analysis for Exosomes / Extracellular Vesicles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Exosomes / Extracellular Vesicles by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| World Current & Future Analysis for Circulating Cell Free RNA (ccfRNA) / miRNA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Circulating Cell Free RNA (ccfRNA) / miRNA by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| World Current & Future Analysis for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| World Current & Future Analysis for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| III. MARKET ANALYSIS |
| UNITED STATES |
| USA Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2020 & 2027 |
| USA Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2020 & 2027 |
| CANADA |
| Canada Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2020 & 2027 |
| Canada Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2020 & 2027 |
| JAPAN |
| Japan Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2020 & 2027 |
| Japan Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2020 & 2027 |
| CHINA |
| China Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2020 & 2027 |
| China Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2020 & 2027 |
| EUROPE |
| Europe Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| Europe 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020 & 2027 |
| Europe Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2020 & 2027 |
| Europe Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2020 & 2027 |
| FRANCE |
| France Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2020 & 2027 |
| France Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2020 & 2027 |
| GERMANY |
| Germany Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2020 & 2027 |
| Germany Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2020 & 2027 |
| ITALY |
| Italy Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2020 & 2027 |
| Italy Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2020 & 2027 |
| UNITED KINGDOM |
| UK Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2020 & 2027 |
| UK Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2020 & 2027 |
| REST OF EUROPE |
| Rest of Europe Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2020 & 2027 |
| Rest of Europe Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2020 & 2027 |
| ASIA-PACIFIC |
| Asia-Pacific Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2020 & 2027 |
| Asia-Pacific Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2020 & 2027 |
| REST OF WORLD |
| Rest of World Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of World 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2020 & 2027 |
| Rest of World Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of World 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2020 & 2027 |
| IV. COMPETITION |
| Total Companies Profiled: 32 |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com